Chlamydia News and Research

Latest Chlamydia News and Research

Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic

Emergent BioSolutions Inc. announced today that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced with the dosing of the first subject. Emergent's fully human monoclonal antibody product candidate is being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.

8 Sep 2010

Emergent BioSolutions signs contract with NIAID to develop third generation anthrax vaccine candidate

Emergent BioSolutions Inc. announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases, an institute within the National Institutes of Health, for advanced development of the company's third generation anthrax vaccine candidate.

2 Sep 2010

Abbott RealTime HBV assay receives marketing approval from FDA

Abbott announced today it has received approval from the U.S. Food and Drug Administration to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus in a patient's blood. It is the first and only approved test capable of automating HBV viral load testing from sample extraction to final results.

2 Sep 2010

Doctoral students receive insights on potential career paths at symposium hosted by Emergent Biosolutions

Emergent BioSolutions Inc.today hosted "Looking Beyond the Bench," a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based industry, provided insight on potential career paths awaiting biomedical researchers.

25 Aug 2010

Emergent BioSolutions enters agreement to acquire Trubion Pharmaceuticals

Emergent BioSolutions Inc. announced today it has entered into a definitive agreement to acquire Trubion Pharmaceuticals, Inc. for upfront consideration of $96.8 million of value and up to $38.7 million of success-based milestones, resulting in a total consideration of up to $135.5 million. The acquisition will diversify Emergent's product development pipeline with the addition of Trubion's two clinical-stage product candidates focused on the targeted disease areas of oncology and autoimmunity.

13 Aug 2010

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

Temasek Life Science Ventures Pte Ltd and Emergent BioSolutions Inc. today announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and commercialize a multivalent, cross-protective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains.

12 Aug 2010

SeraCare optimizes ACCURUN 341 Nucleic Acid Positive controls

SeraCare Life Sciences, Inc. today announced that the Company has developed a new series of controls in its ACCURUN portfolio to monitor and validate molecular diagnostic test performance for detection of Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG). Through collaboration with instrument and reagent manufacturers, SeraCare has optimized the ACCURUN 341 Nucleic Acid Positive controls specifically for use with the three most popular assays currently on the market; the Gen-Probe APTIMA Combo 2 Assay, the Roche COBAS AMPLICOR CT/NG Test, and the Becton, Dickinson BD ProbeTec ET System.

6 Aug 2010

Gen-Probe second-quarter 2010 product sales up 14%

Gen-Probe Incorporated today reported financial results for the second quarter of 2010, highlighted by 14% growth in product sales, 15% growth in total revenues, and 16% growth in non-GAAP earnings per share.

30 Jul 2010

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

DIATHERIX Laboratories ,adds a Sexually Transmitted Disease (STD) panel and Herpes Simplex Virus (HSV) panel to its line up of highly sensitive, rapid response diagnostic panels. The HSV panel identifies herpes simplex viruses 1 and 2 and the STD panel identifies 10 sexually transmitted diseases simultaneously, many of which cannot be accurately identified by current testing methods. These STD organisms, if not appropriately treated, can cause diseases such as syphilis, gonorrhoeae, chlamydia, bacterial vaginosis, etc. and may lead to blindness, infertility or complications during pregnancy.

28 Jul 2010

Abbot's innovative solutions to be highlighted at AACC

A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.

27 Jul 2010

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Abbott today announced financial results for the second quarter ended June 30, 2010.

21 Jul 2010

Cash rewards help combat STIs in rural Africa, study finds

Giving out cash can be an effective tool in combating sexually transmitted infections in rural Africa, according to a new study conducted jointly by researchers at the University of California, Berkeley, the Development Research Group at the World Bank and the Ifakara Health Institute in Tanzania.

20 Jul 2010

Emergent awarded $107M HHS BARDA contract to develop large-scale manufacturing of BioThrax

Emergent BioSolutions Inc. announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale manufacturing of BioThrax® (Anthrax Vaccine Adsorbed) in Building 55. Building 55 is the company's large-scale state-of-the-art vaccine manufacturing facility in Lansing, Michigan.

14 Jul 2010

Emergent BioSolutions hosts forum to raise global awareness of the importance of biopreparedness

Emergent BioSolutions Inc. is hosting "Bioterrorism Prevention, Preparedness and Response," a forum organized for members of the North Atlantic Treaty Organization Parliamentary Assembly to raise global awareness of the importance of biopreparedness.

13 Jul 2010

Inadequate funding for research, prevention will not help eradicate HIV in Quebec

On the XVIII International AIDS Conference's Eve (Vienna, Austria, July 18th to 23rd 2010), Mark Wainberg, PhD, co-director at Réseau Sida/Maladies infectieuses (FRSQ) and Dr. Réjean Thomas, president of clinique médicale l'Actuel denounce chronic underfunding in research and prevention related to HIV in Quebec and it's dramatic impact on the HIV epidemic and STI's. Researchers insist that the government double the amounts dedicated to these sectors.

13 Jul 2010

Erectile dysfunction drug user over 40 more likely to have sexually transmitted diseases

Physicians who prescribe erectile dysfunction drugs for their male patients should be sure to discuss the importance of safer sex practices, even with older patients: that is an important implication of a report in the July 6 issue of Annals of Internal Medicine. The analysis of insurance records of more than 1.4 million U.S. men over 40 found that those who used ED drugs were more likely to have sexually transmitted diseases than were non-users.

6 Jul 2010

Gen-Probe's APTIMA Trichomonas assay receives European CE mark

Gen-Probe Incorporated announced today that it has received a European CE mark for its APTIMA® assay for Trichomonas vaginalis, a common parasitic sexually transmitted disease.

1 Jul 2010

FDA grants Abbott 510(k) clearance to market molecular diagnostic test for detection of chlamydia, gonorrhea

Abbott announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market a new, sensitive molecular diagnostic test and instrument to simultaneously detect two of the nation's most prevalent sexually transmitted diseases (STDs), gonorrhea and chlamydia, including a new variant strain of chlamydia recently discovered in Sweden.

28 Jun 2010

Emergent BioSolutions completes sales, deliveries of BioThrax to allied international governments

Emergent BioSolutions Inc. announced today that it has completed separate international sales and deliveries of BioThrax® (Anthrax Vaccine Adsorbed) to governments of several allied nations. The company's international sales efforts have resulted in these sales of an undisclosed number of BioThrax doses for aggregate revenue of approximately $2.3 million in the second quarter.

24 Jun 2010

Small molecule ramps up interferon production in host cells, launching potent immune response

Many disease-causing microbes carry pumps that expel antibiotics, making the bugs hard to kill with standard drugs. Ironically, these same pumps could be the bugs' Achilles heel.

28 May 2010

Chlamydia News and Research

Latest Chlamydia News and Research

Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic

Emergent BioSolutions signs contract with NIAID to develop third generation anthrax vaccine candidate

Abbott RealTime HBV assay receives marketing approval from FDA

Doctoral students receive insights on potential career paths at symposium hosted by Emergent Biosolutions

Emergent BioSolutions enters agreement to acquire Trubion Pharmaceuticals

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

SeraCare optimizes ACCURUN 341 Nucleic Acid Positive controls

Gen-Probe second-quarter 2010 product sales up 14%

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

Abbot's innovative solutions to be highlighted at AACC

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Cash rewards help combat STIs in rural Africa, study finds

Emergent awarded $107M HHS BARDA contract to develop large-scale manufacturing of BioThrax

Emergent BioSolutions hosts forum to raise global awareness of the importance of biopreparedness

Inadequate funding for research, prevention will not help eradicate HIV in Quebec

Erectile dysfunction drug user over 40 more likely to have sexually transmitted diseases

Gen-Probe's APTIMA Trichomonas assay receives European CE mark

FDA grants Abbott 510(k) clearance to market molecular diagnostic test for detection of chlamydia, gonorrhea

Emergent BioSolutions completes sales, deliveries of BioThrax to allied international governments

Small molecule ramps up interferon production in host cells, launching potent immune response

Forensics and toxicology - Industry Focus eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Chlamydia News and Research

Latest Chlamydia News and Research

Forensics and toxicology - Industry Focus eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in